Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(TM) therapeutic devices, this morning announced its appointment of Peter Novak, M.D., Ph.D., to its scientific advisory board. According to the update, Novak is a board-certified neurologist and autonomic specialist who serves as the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. In addition, he is a member of the American Academy of Neurology, the American Autonomic Society and the Autonomic Board of United Council for Neurologic Subspecialties. “The Endonovo team is delighted to welcome Dr. Novak to the Scientific Board,” Endonovo CEO Alan Collier stated in the news release. “Peter’s experience will add significant value to our oversight as we transition to and advance our differentiated development programs in Electroceuticals(TM). We also welcome the insights of Dr. Novak, whose expertise in key areas relating to our programs will inform both our clinical and post-operative strategies.”
To view the full press release, visit http://nnw.fm/j9Ksj
About Endonovo Therapeutics Inc.
Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable electroceuticals(TM) therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable electroceuticals therapeutic devices addresses wound healing, pain, postsurgical pain and edema, cardiovascular disease, chronic kidney disease and central nervous system (“CNS”) disorders, including traumatic brain injury (“TBI”), acute concussions, postconcussion syndrome and multiple sclerosis. The company’s noninvasive electroceutical therapeutic device, SofPulse(R), using pulsed short-wave radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the palliative treatment of soft-tissue injuries and postoperative pain and edema, and has CMS national coverage for the treatment of chronic wounds. The company’s current portfolio of preclinical-stage electroceuticals therapeutic devices address chronic kidney disease, liver disease nonalcoholic steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”), and ischemic stroke. The company’s noninvasive, wearable electroceuticals therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for healing to occur. For more information, visit the company’s website at www.Endonovo.com
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://nnw.fm/ENDV
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com